Seven Theatres of Content


The Main Stage will discuss advances in sequencing technologies, long- and short- read sequencing, and how researchers are making the most of these technologies for rapid insights. On day 2, The Main Stage will discuss innovations in cancer diagnostics and precision oncology to inspire the next generation of cancer care and therapeutics through epigenomics and more. We end day 2 with “The Shark Tank."


The Biodata Stage will showcase the latest approaches towards big data storage, management and access including cloud computing, federated platforms and data harmonization methods. The Biodata Stage will also explore how the latest platforms are supporting the integration of genomic, clinical and imaging data for a multi-modal approach to precision health data science. The Biodata Stage will also explore how AI and LLMs are making their way towards the clinic and the advantages this is set to bring patients and clinicians.


The Single-Cell and Spatial Stage will cover advances in single-cell and spatial technologies, how to choose the best technology for your research question, advances in data analysis methods, and novel insights gained from leveraging these technologies.


The Innovation Stage will explore genomics in women’s health, highlighting risk prediction and predisposition to PCOS and gynaecologic cancers. It will cover advances in pre-natal and neonatal testing to identify early disease risks. The Innovation Stage will showcase recent innovations in RNA therapeutics, delivery and cancer vaccines to enable robust mRNA design for delivery and vaccine development.


Image Panels The Live Lounge will cover cancer genomics and epigenetics, touching on MRD, multi-omics integration, spatial transcriptomics and EGFR signaling. It will highlight the interplay between genetic and epigenetic regulation during disease progression and therapeutic response. The Live Lounge will also explore genomics in society, highlighting how diverse patient populations support rare disease diagnosis, polygenic risk scores and how genomics influences psychiatric traits and alcohol use disorder.


The Omics Stage will cover how high-throughput proteomics is quickly becoming an effective drug development tool within the realms of biomarker discovery, target ID and developing personalised treatment strategies. We’ll also explore the latest translational applications of proteomics and how researchers are not only looking to study entire proteomes but also protein networks within single cells. The Omics Stage will cover advances in genome editing tools that improve safety and efficacy of immunotherapies. It will also cover recent technologies in gene therapy for regenerative medicine and solid cancers.


The Discovery Stage will discuss advances in drug discovery and translational research. The stage covers AI, harnessing the strength of multi-omics and big data for drug discovery and development. The Discovery Stage will cover microbiome and metagenomics, discussing the role of disease-specific microbiota in early life and neurologic diseases to inform clinical interventions.